DDO-02267 is a selective and lysine-targeting covalent inhibitor of ALKBH5 , with an IC 50 value of 0.49 μM. DDO-02267 increases N 6 -methyladenosine (m 6 A) levels and targets the ALKBH5-AXL signaling axis. DDO-02267 can serve as a probe for investigating the biological function of mRNA demethylase.
Products | Products > Disease Areas > Cancer | Products > Signaling Pathways > Protein Tyrosine Kinase/RTK | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Anaplastic lymphoma kinase (ALK) | Products > Signaling Pathways > Fat Mass and Obesity-associated Protein (FTO)
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.